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Plenary paper
HOXA9 is required for survival in human MLL-rearranged acute leukemias
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Leukemias that harbor translocations in-
volving the mixed lineage leukemia gene
(MLL) possess unique biologic character-
istics and often have an unfavorable prog-
nosis. Gene expression analyses demon-
strate a distinct profile for MLL-rearranged
leukemias with consistent high-level ex-
pression of select Homeobox genes, in-
cluding HOXA9. Here, we investigated the
effects of HOXA9 suppression in MLL-
rearranged and MLL-germline leukemias
using RNA interference. Gene expression
profiling after HOXA9 suppression dem-
onstrated co–down-regulation of a pro-
gram highly expressed in human MLL-
AML and murine MLL-leukemia stem cells,
including HOXA10, MEIS1, PBX3, and
MEF2C. We demonstrate that HOXA9
depletion in 17 human AML/ALL cell lines
(7 MLL-rearranged, 10 MLL-germline) in-
duces proliferation arrest and apoptosis
specifically in MLL-rearranged cells
(P  .007). Similarly, assessment of pri-
mary AMLs demonstrated that HOXA9
suppression induces apoptosis to a
greater extent in MLL-rearranged samples
(P  .01). Moreover, mice transplanted
with HOXA9-depleted t(4;11) SEMK2 cells
revealed a significantly lower leukemia
burden, thus identifying a role for HOXA9
in leukemia survival in vivo. Our data
indicate an important role for HOXA9 in
human MLL-rearranged leukemias and
suggest that targeting HOXA9 or down-
stream programs may be a novel thera-
peutic option. (Blood. 2009;113:2375-2385)
Introduction
Translocations involving the mixed lineage leukemia locus (MLL,
All-1, HRX) on chromosome 11q23 are found in a variety of
hematologic malignancies, including acute myeloid leukemias
(AMLs), B-precursor and T-lineage acute lymphoblastic leuke-
mias, and myelodysplastic syndrome. MLL rearrangements are
present in most infant leukemias1-4 and in secondary leukemias
after treatment with topoisomerase inhibitors.5-8 Infants diagnosed
with lymphoblastic leukemia harboring a MLL translocation re-
spond poorly to current chemotherapy regimens and have a
particularly unfavorable prognosis with an overall survival of
less than 50%.9-13
The pathophysiologic mechanisms by which MLL transloca-
tions cause leukemia and the genes that serve as critical down-
stream targets during induction and maintenance of the leukemic
phenotype are incompletely characterized. Gene expression profil-
ing in human acute myeloid and lymphoblastic leukemias demon-
strated a characteristic gene expression pattern for cases with MLL
rearrangements14-16 that may be driven by unique histone methyl-
ation programs.17-20 A common unifying feature in myeloid and
lymphoid leukemias with MLL rearrangements is high-level expres-
sion of Homeobox (HOX) genes with a particular emphasis on the
5-HOXA genes (HOXA5-11).14-16,21,22 Elevated expression of cer-
tain 5-HoxA cluster genes is also found in murine leukemia models
after introduction of various leukemia-associated Mll-fusion pro-
teins.23-27 In a recent murine retroviral transduction/transplantation
study, we determined the gene expression profile of leukemia stem
cells that were initiated by expression of Mll-Af9 in committed
granulocyte macrophage progenitors (GMPs).28 5-HoxA cluster
genes HoxA5, HoxA10, and in particular HoxA9 were prominent
members of a gene expression signature found in leukemia stem
cells and were immediately induced after Mll-Af9 expression.28
These findings support a hierarchical model of leukemia initiation
by the MLL-AF9 fusion where certain HOXA cluster genes belong
to a crucial subset of proximate target genes, which are immedi-
ately activated by MLL-AF9 expression.28,29 Further evidence that
MLL fusion oncoproteins may directly regulate certain HOX genes
in hematopoietic cells emerges from recent studies in which
wild-type MLL or MLL fusion proteins were found to be part of a
multiprotein complex that regulates chromatin structure near the
5-HOXA cluster.30-33
HOXA9 is directly involved in human leukemia caused by the
translocation of HOXA9 with the gene encoding NUP98, a nucleoporin
protein.34,35 Expression of this fusion protein immortalizes murine bone
marrow cells and results in a myeloproliferative disorder and AML in
bone marrow transplantation experiments.36,37 Retrovirally enforced
overexpression of HOX genes in murine and human marrow cells
enhances expansion of hematopoietic cells in short-term in vitro
cultures, and murine transplantation studies showed that forced expres-
sion of HoxA9 in hematopoietic precursors results in a significant
expansion of hematopoietic stem cells and leukemia.38-43 Moreover,
coexpressing HoxA9 suppresses Meis1-mediated apoptosis in a variety
of murine and human leukemia cell types.44
During normal hematopoietic development, HOX genes are
expressed in the stem cell and immature progenitor compartments
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of bone marrow but are transcriptionally down-regulated on
induction of terminal differentiation.45-47 Homozygous HoxA9-
deficient mice are viable but exhibit a variety of mild hematopoietic
defects, including reduced number of committed myeloid and
B-cell progenitors and a blunted neutrophilic response to granulo-
cyte colony-stimulating factor.48,49 HoxA9-deficient hematopoietic
stem cells (HSCs) demonstrate an impaired proliferative response
to cytokines in vitro and defective competitive repopulating
activity in vivo.50 Thus, HoxA9 does appear to play a role in normal
HSC biology, but is not essential for HSC development.
Although most studies point to some role for HOX genes in
myeloid leukemogenesis, it remains unclear whether continued
expression of any HOXA cluster gene is necessary for survival
of AMLs. Murine studies addressing this issue have provided
mixed results. Mll-Enl–transduced murine myeloid progenitors
deficient for HoxA9 demonstrate significantly compromised
self-renewal potential in vitro and impaired development of
leukemias when transplanted in vivo.27 However, HoxA9/-
deficient progenitors transduced with Mll-Gas7 are capable of
initiating leukemia,51 and Mll-Af9, HoxA9/ mice develop
leukemia with a similar frequency and latency as mice carrying
Mll-Af9 with germline HoxA9.24 These studies raise the issue as
to whether there is compensation for the lack of HoxA9 during
development, and prompt assessment of an acute loss of HOXA9
expression in a fully developed leukemia. In this study, we
aimed to further elucidate the role of HOXA9 expression in
human MLL-rearranged and nonrearranged leukemias. Through
use of a small hairpin RNA (shRNA)–mediated RNA interfer-
ence approach and subsequent gene expression profiling analy-
sis, we demonstrate a marked impact of HOXA9 suppression on
survival of human MLL-rearranged leukemia cells associated
with tight co–down-regulation of genes that were part of a MLL
signature in primary human samples.
Methods
Generation of murine leukemia stem cells
Murine leukemic granulocyte macrophage progenitors (L-GMPs) were
generated as described previously28 (Document S1, available on the Blood
website; see the Supplemental Materials link at the top of the online article).
For HOXA9 shRNA knockdown experiments, IL-7RLinSca-1c-
KitCD34-FcgRII/III GMP-like leukemic cells (L-GMPs) sorted from
leukemic mice were incubated with lentiviral shRNA vectors and plated in
methylcellulose media M3234 or liquid culture (Myelocult M5300;
StemCell Technologies, Vancouver, BC) supplemented with 10 ng/mL IL-3
(PeproTech, Rocky Hill, NJ), 1 penicillin/streptomycin (Invitrogen,
Carlsbad, CA). All mouse studies were approved by the Dana Farber
Cancer Institute Institutional Animal Care and Use Committee.
Leukemia primary patient samples
Pediatric AML samples were obtained from the Erasmus MC, Sophia
Children’s Hospital (Rotterdam, The Netherlands). Approval was obtained
from the Erasmus MC Institutional Review Board for these studies.
Informed consent was obtained in accordance with the Declaration of
Helsinki. Analyzed samples consisted of cryopreserved cells of AML
patients with confirmed rearrangement of the MLL locus determined by
either cytogenetic analysis, fluorescence in situ hybridization, or Southern
blot and AML patients with MLL germline karyotype. Patient samples 1, 2,
3, 5, and 6 harbored a t(9;11). Sample 4 possessed a t(11;19). Mean
percentage of blasts was approximately 90%. Although a variable number
of dead cells was observed after thawing in the same range as previously
demonstrated,52 culture conditions were optimized to support 50% to 60%
viable cells at 72 to 96 hours for subsequent phenotypic assays (see
Document S1).
Transfection with shRNA constructs
shRNA cloned into hairpin pLKO.1-lentiviral vector were kindly synthe-
sized by the Harvard/MIT Broad Institute RNA consortium using a complex
selection algorithm to minimize off-target effects (http://www.broad.mit.edu/
rnai/trc). Lentiviral supernatants were obtained in 293T cells by cotransfec-
tion of the shRNA plasmids, packaging plasmids containing gag, tat, and
rev genes, and a plasmid expressing VSV-G. For lentiviral infection of
leukemia cell lines or primary AML patient cells, 105 cells were seeded in
96-well tissue culture plates (100 L per well) in the appropriate culture
media. Polybrene (hexadimethrine bromide; Sigma-Aldrich, St Louis, MO)
was added at a final concentration of 7 g/mL. After adding 150 L
lentiviral particles (titer of each lentiviral shRNA construct adjusted to
1.6  106 transducing units/mL to achieve a multiplicity of infection of
2.4 transducing units/cell), spinoculation was performed at 2250g for
90 minutes at 37°C. Eight hours after infection, the media was replaced
with 100 L of the appropriate fresh culture media. If puromycin selection
was desired, puromycin dihydrochloride (Sigma-Aldrich) at a final concen-
tration of 2.5 g/mL was added. Cells were incubated at 37°C, 5% CO2
until use for downstream applications (see Document S1).
Analysis of cell viability and apoptosis
To assay cell viability, we used the colormetric diphenyltetrazolium
bromide (MTT) Cell Proliferation Kit I (Roche Diagnostics, Indianapolis,
IN) according to the instructions of the manufacturer and flow cytometric
analysis after fluorescein isothiocyanate–annexin V (BioVision, Mountain
View, CA)/propidium iodide (Invitrogen) double staining. Cell-cycle
analysis was performed by flow cytometric analysis of propidium iodide-
stained cells at defined time points after shRNA transduction.
Murine transplantation experiments and in vivo imaging
Luminescent t(4;11) SEMK2-M1 cells were generated, and bioluminescent
in vivo imaging was performed as previously described53 (Document S1).
For further postmortem analysis of mouse leukemia burden, single-cell
suspensions were generated from spleen. Red blood cells were lysed on ice
using red blood cell lysis solution (Gentra Systems, Minneapolis, MN) for
5 minutes. After centrifugation, cells were resuspended in phosphate-
buffered saline supplemented with 10% fetal bovine serum. A total of
5  108 of nucleated cells were incubated 40 minutes on ice with 10 L of
each of the following fluorochrome-conjugated antibodies: mouse anti–
human CD19-TC (Invitrogen), anti–mouse CD45.2-fluorescein isothiocya-
nate (BD Biosciences, San Jose, CA). After a double wash in phosphate-
buffered saline, the cell suspension was sorted using FACSAria multicolor
cell sorter (BD Biosciences).
Data analysis and statistical methods
After hybridization to Affymetrix Human Genome U133A2.0 microarrays
(Santa Clara, CA), data were analyzed using the GenePattern 3.0 software
package,54 including the Gene set enrichment analysis (GSEA) module55
(Broad Institute; Document S1). All other statistical calculations were
performed using SPSS 14.0 software package (SPSS, Chicago, IL). The
original microarray data have been deposited into the Gene Expression
Omnibus database, under accession number GSE13714.
Results
Establishment and validation of HOXA9 suppression in human
leukemia cells
To establish efficient knockdown targeting the human HOXA9
mRNA, 5 different shRNA constructs (1F2-HOXA9shRNA, 1F3-
HOXA9shRNA, 2A4-HOXA9 shRNA, 2A5-HOXA9shRNA, and
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2A6-HOXA9shRNA) were stably introduced into target cells of
interest using a lentiviral vector system. The shRNA sequences
were selected using an algorithm that enhances the likelihood of
efficient RNA interference (RNAi) and minimizes targeting of
other mRNAs.56 Genome-wide blast search demonstrated at least
6 sequence mismatches for any other gene in the human genome
database. First, we assessed transduction efficiency using the green
fluorescent protein (GFP)–control shRNA construct in 17 different
MLL-rearranged and MLL wild-type leukemia cell lines by selec-
tion in puromycin and demonstrated a high percentage of puromy-
cin resistance ( 80% transduction efficiency), which was similar
in each cell line tested (Figure S1), whereas nontransduced control
cells of each type were effectively eliminated (not shown). Thus, all
subsequent experiments were performed without puromycin selec-
tion. We then introduced each of the HOXA9 targeting shRNAs into
t(9;11) MOLM-14 cells and t(4;11) SEMK2-M1 (SEMK2) cells
and compared the suppression efficiency to cells that were trans-
duced with either a nontargeting control shRNA directed toward
GFP, an empty lentiviral vector, or untreated. Using quantitative
real-time polymerase chain reaction (PCR), we found that 3 of
5 HOXA9shRNA constructs (1F2-HOXA9shRNA, 1F3-
HOXA9shRNA, and 2A5-HOXA9shRNA) suppressed HOXA9
RNA levels by at least 80% compared with control. The 2A4-
HOXA9shRNA construct showed a more variable effect (60%-
80% suppression; Figure 1A), and the 2A6-HOXA9shRNA had
only minimal effect (not shown) and was therefore excluded from
further experiments. The efficacy of HOXA9 suppression by the
4 effective constructs was confirmed by Western blot analysis
(Figure 1A). Because introduction of some RNAi constructs has
been previously found to unspecifically induce interferon re-
sponse,57 we next analyzed expression changes in the interferon
response genes OAS1, IFITM1, and MX1 by quantitative real-time
PCR as suggested in recent guidelines.58 Transduction of any of the
lentiviral constructs showed no induction of the interferon response
genes analyzed with expression levels similar to untreated control
cells (Figure S2). Thus, we have validated 4 independent shRNA
constructs that suppress HOXA9 expression in MLLAF9 and
MLLAF4 human leukemia cell lines.
Effects of HoxA9 knockdown in murine leukemia stem cells
In our recent murine Mll-Af9 transduction/transplantation study,
gene expression profiling revealed aberrant expression of HoxA9
as part of a stem cell signature in a IL-7RLinSca-1c-
KitCD34FcgRII/III GMP-like (L-GMP) leukemia stem cell
population.28 We therefore first explored the effects of HoxA9
depletion in this well-defined and previously characterized
murine leukemia stem cell population. To achieve maximum
HoxA9 knockdown in murine L-GMP, the 2 most effective
HOXA9 shRNA constructs with 100% target sequence homol-
ogy between the human and murine HOXA9 gene were selected
(1F2-HOXA9shRNA, 1F3-HOXA9shRNA). These constructs
had already been previously successfully used in murine
hematopoietic cells.59 Using quantitative real-time PCR, we
found that both shRNA constructs efficiently suppressed HOXA9
RNA levels in L-GMP compared with cells transduced with a
nontargeting control shRNA (Figure S3). L-GMP cells were
Figure 1. ShRNA-mediated knockdown of HOXA9 expression
in human t(9;11) MOLM-14 and t(4;11) SEMK2 cells and
murine leukemia stem cells (L-GMP). (A) Quantitative real-time
PCR analysis of HOXA9 expression 72 hours after transduction of
MOLM-14 and SEMK2 cells with 1 of 4 different HOXA9 shRNA
constructs (1F2-HOXA9shRNA, 1F3-HOXA9shRNA, 2A4-
HOXA9shRNA, and 2A5-HOXA9shRNA) without puromycin se-
lection. A highly efficient HOXA9 suppression is demonstrated
compared with a nontargeting control shRNA directed toward
GFP. Western blot analysis 72 hours after transduction confirmed
HOXA9 protein knockdown. (B) HoxA9 depletion in highly purified
murine leukemia stem cells (L-GMP) resulted in a progressive
induction of apoptosis in liquid culture compared with cells
transduced with a control shRNA. (C) Analysis of L-GMP colony
formation and replating capacity after HoxA9 suppression. Colo-
nies were counted and replated at day 8. A significant decrease in
colony number and replating capacity is demonstrated for
L-GMPs transduced with HoxA9-directed shRNA without puromy-
cin selection. (D) Analysis of L-GMP colony formation after
HOXA9 suppression in a mixed-populations assay. L-GMPs were
transduced with 1F2-HOXA9shRNA, 1F3-HOXA9shRNA, or GFP-
control shRNA constructs, and populations of HOXA9shRNA or
GFP-control shRNA-transduced cells were mixed in a ratio of 9:1
(HOXA9shRNA-transduced cells/GFP-control shRNA-transduced
cells) and plated in semisolid medium. The total number of
colonies at day 8 is shown for the mixed populations (1F2-
HOXA9shRNA/GFP-control-shRNA; 1F3-HOXA9shRNA/GFP-
control-shRNA) and the controls containing only GFP-control
shRNA-transduced cells. (E) Quantitative real-time PCR further
demonstrated similar HOXA9 expression in colonies that arose
from the mixed HOXA9shRNA/GFP-control shRNA populations
and controls containing only GFP-control shRNA-transduced
cells (day 8).
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transduced with either the 1F2-HOXA9shRNA or the 1F3-
HOXA9shRNA construct, and viability in liquid culture supple-
mented with cytokines was compared with L-GMP cells that
were transduced with a nontargeting control shRNA. Whereas
control shRNA-transduced cells survived in liquid culture,
L-GMPs transduced with either the 1F2-HOXA9shRNA or
1F3-HOXA9shRNA construct showed a progressive induction
of cell death with onset short after transduction, leading to
almost complete loss of viable cells at day 3 (Figure 1B). Next,
we analyzed colony-forming and replating capacity of L-GMPs
transduced with 1F2-HOXA9shRNA, 1F3-HOXA9shRNA, or
control shRNA constructs in semisolid medium. At day 8,
colony formation was significantly reduced in the 2 L-GMP
populations transduced with either the 1F2-HOXA9shRNA or
1F3-HOXA9shRNA construct demonstrating a colony count of
less than 10% of the control shRNA treated group (Figure 1C).
Moreover, replating and reevaluation at day 16 revealed a more
than 10-fold expansion in the control L-GMP population,
whereas colony-forming activity was completely abrogated in
the HoxA9 shRNA-transduced populations (Figure 1C). Further-
more, analysis of colony-forming capacity of L-GMP in a
mixed-populations assay demonstrated similar findings: L-
GMPs were transduced with the 1F2-HOXA9shRNA, 1F3-
HOXA9shRNA, or GFP-control shRNA construct. Cells were
then mixed in a ratio of 9:1 (HOXA9shRNA-transduced cells:
GFP-control shRNA-transduced cells) and plated in semisolid
medium with cytokines. At day 8, a significantly lower number
of colonies was observed in the 1F2-HOXA9shRNA/GFP-
control shRNA and 1F3-HOXA9shRNA/GFP-control shRNA
mixed populations compared with controls containing only cells
transduced with GFP-control-shRNA (Figure 1D). Quantitative
real-time PCR further demonstrated HOXA9 expression levels
in the mixed populations similar to those of the controls (Figure
1E), indicating that only cells with nonsuppressed HOXA9
expression were capable of colony formation. These findings
point toward a central role for HoxA9 in the maintenance of
murine Mll-rearranged leukemia stem cells. We therefore sought
to further characterize the effects of HOXA9 depletion in human
leukemia cell lines and primary leukemia patient samples.
Effects of HOXA9 suppression in human MLLAF4 SEMK2 and
MLLAF9 MOLM-14 leukemia cells
To examine the effect of HOXA9 suppression on the cellular
phenotype in human leukemia cells, we first analyzed apoptosis
induction as measured by annexin V/PI positivity after transduc-
tion of t(9,11) MOLM-14 AML M5 and t(4;11) SEMK2 ALL
cells with each of the 4 HOXA9 targeted shRNAs or GFP-
control shRNA. HOXA9 suppression led to a significant reduc-
tion of cell viability with all 4 HOXA9shRNA constructs
compared with control (Figure 2A). In an independent experi-
ment, time course analysis of apoptosis induction further
demonstrated progressive reduction of cell viability starting
72 to 84 hours after transduction (Figure 2B). Induction of cell
death was preceded by inhibition of proliferative capacity as
assessed by MTT assay approximately 24 hours before induc-
tion of cell death became evident (48 hours after transduction;
Figure S4).
Next, to further assess specificity of the observed correlation
between HOXA9 suppression and induction of apoptosis, GFP-
HOXA9 was ectopically overexpressed in MOLM-14 cells.
GFP-positive cells were sorted and HOXA9 overexpression was
confirmed by quantitative real-time PCR and Western blot
analysis (Figure 2C). Transduction with the 2A4-HOXA9shRNA
Figure 2. Analysis of phenotypic consequences after shRNA-
mediated HOXA9 suppression in t(9;11) MOLM-14 AML and
t(4;11) SEMK2 ALL cells. (A) Analysis of cell viability as mea-
sured by annexin V/PI positivity at day 7 after transduction of
t(9,11) MOLM-14 cells and t(4;11) SEMK2 cells with 1 of 4 HOXA9
targeted shRNAs or GFP control shRNA. The percentage of
viable (annexin V/PI negative) cells is shown in the HOXA9shRNA
and GFP control shRNA-transduced group. (B) Time course
analysis of cell viability as measured by annexin V/PI positivity
after HOXA9 suppression in an independent experiment. Cells
were transduced with either 1 of 4 HOXA9 targeted shRNAs or
GFP-control shRNA. The data are graphed as percentage of
viable cells that were transduced with HOXA9shRNA/percentage
of viable cells that were transduced with GFP-control shRNA at a
given time point. These results were confirmed 3 times.
(C) Quantitative real-time PCR and Western blot analysis of
ectopic HOXA9 overexpression in t(9;11) MOLM-14 cells com-
pared with untransduced cells and cells transduced with the
empty vector construct. (D) MOLM-14 cells ectopically overex-
pressing HOXA9 were transduced with the 2A4-HOXA9shRNA
construct specifically targeting the 3-untranslated region of
endogenous HOXA9 or the GFP-control shRNA construct. Ec-
topic overexpression of HOXA9 almost completely rescued the
phenotype (annexin V/PI staining).
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construct to specifically target the 3-untranslated region of
endogenous HOXA9 demonstrated almost complete rescue of
the phenotype with a high level of protection by ectropic
overexpression of nontargetable HOXA9 compared with con-
trols (Figure 2D). Rescue of the phenotype by ectopically
expressing a nontargetable HOXA9 construct was also con-
firmed in an independent experiment in t(9;11) THP-1 cells
applying siRNA-mediated HOXA9 suppression (Figure S5).
To further assess the effects on proliferation and viability
after HOXA9 depletion, we analyzed cell cycle status. A time
course analysis of MOLM-14 cells transduced with the 1F3-
HOXA9shRNA construct revealed a progressive increase of
cells in the G1 phase and a decrease in G2 and S phases, 24 to
36 hours before the prominent induction of cell death (Figure
3A). These findings are suggestive of an accumulation of the
HOXA9shRNA-transduced cell population in G1 phase before
progressively undergoing apoptosis. We next analyzed whether
HOXA9 depletion might induce differentiation before apoptosis.
Analysis of mRNA expression of myeloid differentiation mark-
ers M-CSF1R, PU.1, and ITGAM (CD11b) and granule mol-
ecules associated with terminal myeloid differentiation (ly-
sozyme [LYZ]), myeloperoxidase [MPO]), elastaseA2 [ELA2])
by quantitative real-time PCR demonstrated a significant induc-
tion of these markers 72 hours after HOXA9shRNA transduc-
tion compared with GFP shRNA-transduced control cells (Fig-
ure 3B). Fluorescence-activated cell sorter analysis of the
myeloid differentiation marker CD14 in MOLM-14 cells re-
vealed a significant increase in CD14 expression in cells
transduced with HOXA9 shRNA constructs compared with
controls (Figure S6). Induction of CD14 expression was detect-
able as early as 48 hours after shRNA transduction and reached a
peak at 84 hours (GFP shRNA, 1.62%; 1F3-HOXA9shRNA,
14.61%; 2A5-HOXA9shRNA, 17.58%) shortly before progres-
sive induction of cell death set in (Figure S6). These data
indicate that HOXA9 depletion initiates some degree of cellular
differentiation before induction of apoptosis.
Figure 3. Effects of HOXA9 suppression in human t(9;11) MOLM-14 and t(4;11) SEMK2 cells. (A) Fluorescence-activated cell sorter analysis of cell-cycle status after
transduction of MOLM-14 cells with 1F3-HOXA9shRNA after PI staining. A progressive increase of cells in G1 phase and a decrease of cells in G2 and S phases were noted
compared with control GFP-shRNA–transduced cells with onset 24 to 36 hours before induction of apoptosis. (B) Analysis of mRNA expression of myeloid differentiation
markers M-CSF1R, PU.1, and ITGAM (CD11b) and the granule molecules lysozyme (LYZ), myeloperoxidase (MPO), and elastaseA2 (ELA2) associated with terminal myeloid
differentiation by quantitative real-time PCR 72 hours after HOXA9shRNA transduction. Compared with control GFP-shRNA transduced cells, a significant induction of mRNA
expression was observed. (C) Gene expression analysis 44 hours after HOXA9 suppression in t(9;11) MOLM-14 cells with 2 different HOXA9shRNAs (1F3-HOXA9shRNA;
2A5-HOXA9shRNA) in triplicates compared with GFP-shRNA–transduced controls. Analysis of concomitant expression changes in other Homeobox A-D cluster genes
demonstrated co–down-regulation of 5-HOXA cluster gens in the HOXA9 suppression signature. (D) GSEA of the top 500 genes down-regulated after HOXA9 suppression in
a gene expression dataset of 56 human AML patients.60 The HOXA9 suppression gene set is significantly enriched in a signature previously identified as more highly expressed
in MLL-AML compared with other genetically defined AML subtypes (ES  0.48; P  .001). (E) Confirmation of co–down-regulation of 5-HOXA cluster genes as well as the
HOXA9 cofactors MEIS1 and PBX3 and the transcription factor MEF2C in t(4;11) SEMK2 cells (quantitative real-time PCR analysis).
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Gene expression analysis after HOXA9 suppression
Next, we used gene expression profiling to characterize changes
that occur after HOXA9 suppression in t(9;11) MOLM-14 cells.
RNA was purified 44 hours after transduction in triplicates with
2 of the 2 most effective HOXA9shRNA constructs (3  1F3-
HOXA9shRNA; 3  2A5-HOXA9shRNA) or GFP-control
shRNA (6 ) and hybridized to Affymetrix Human Genome
U133A2.0 microarrays. Initial comparative marker analysis of
expression changes applying either one of the HOXA9shRNAs
against GFP-control shRNA identified large groups of genes
with decreased expression in cells treated with both HOXA9-
directed shRNA constructs. GSEA55 further demonstrated al-
most complete overlap of the top 500 gene probes with
decreased expression after HOXA9 suppression applying the
2 different HOXA9-shRNAs (enrichment score [ES]  0.82,
P  .001; Figure S7A). Having established that both HOXA9-
shRNAs led to almost identical expression changes after
HOXA9 suppression, both datasets were combined for further
analysis. Among the genes with the most significantly decreased
expression after HOXA9 suppression were genes previously
identified as important in leukemogenesis and self-renewal of
leukemia stem cells, such as the HOXA9 cofactor MEIS1,
MEF2C, a member of the myocyte enhancer factor 2 gene
family of transcription factors and BMI1 (Figure S7B). We then
aimed to determine whether HOXA9 suppression leads to
concomitant changes in other Homeobox A-D cluster genes.
Assessment of expression changes in a panel of Homeobox A-D
cluster genes demonstrated concomitant co–down-regulation of
a subset of 5-HOXA cluster genes, including HOXA7 and
HOXA10 (Figure 3C). Next, to assess the relevance of the
HOXA9 suppression signature in primary human AML, we
determined whether there was significant overlap between our
data and a gene expression signature in primary human MLL-
rearranged AML.60 GSEA demonstrated significant overlap
between the top 500 genes that decreased in expression after
HOXA9 suppression (Figure S7B) and genes more highly
expressed in human MLL-AML compared with other geneti-
cally defined AML subtypes (ES  0.48; P  .001; Figure 3D).
These overlapping gene sets further validated genes previously
implicated in the pathogenesis of MLL-rearranged leukemias,
including the HOXA9 cofactors MEIS1 and PBX3, MEF2C, and
BMI1 (Figure 3D). Co–down-regulation of 5-HOXA-cluster
genes and the HOXA9 cofactors MEIS1 and PBX3 as well as the
myocyte enhancer factor 2c (MEF2C) after HOXA9 suppression
was also demonstrated in t(4;11) SEMK2 cells (Figure 3E).
These data demonstrate an important role for HOXA9 as an
upstream regulator of an MLL-AF9–associated gene expression
program.
Effect of HOXA9 suppression in human leukemia cell lines and
primary human leukemias
Next, we analyzed whether the observed induction of apoptosis
after HOXA9 suppression is specific for t(9;11) MOLM-14 and
t(4;11) SEMK2 cells or whether a similar phenotype can also be
identified in an extended panel of MLL-rearranged and MLL-
wild-type cell lines. In a panel of 11 AML/ALL cell lines
(6 MLL-rearranged; 5 MLL-wild-type), a significantly higher
induction of cell death was demonstrated in the MLL-rearranged
Figure 4. Induction of apoptosis by HOXA9 suppression is significantly correlated with the presence of the MLL-fusion oncogene. (A) Analysis of cell viability at day 7
after HOXA9 shRNA transduction in a larger panel of 11 AML/ALL cell lines (6 MLL-rearranged; 5 MLL-wild-type) showing significantly higher apoptosis induction in
MLL-rearranged cells with all 4 HOXA9shRNA constructs. (B) Independent analysis in a panel of 17 AML/ALL cell lines (7 MLL-rearranged; 10 MLL-wild-type) further
demonstrated a significant correlation between cell number and baseline HOXA9 expression after shRNA-mediated suppression, with the greatest effect in cell lines
expressing the highest HOXA9 levels (R  0.8: P  .001; F, MLL-rearranged cell lines; , MLL-wild-type cell lines).
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group after transduction with each of the 4 HOXA9shRNA
constructs, revealing a differential effect on viability that is
significantly more prominent in MLL-rearranged leukemia cells
(Figure 4A). Next, we reasoned that induction of apoptosis via
specific suppression of HOXA9 might manifest as a correlation
between HOXA9 expression and cellular sensitivity. In an
independent experiment, determination of baseline HOXA9
expression before HOXA9 suppression (Figure S9A) and analy-
sis of viability after HOXA9shRNA transduction by MTT assay
in a panel of AML and ALL cell lines (Figure S9B) identified a
significant correlation between cell number and baseline HOXA9
mRNA expression, with the greatest effect on viability in cells
expressing the highest HOXA9 levels (R  0.8, P  .001;
Figure 4B). These data demonstrate that continued HOXA9
expression is important for leukemia cells expressing HOXA9 at
high levels and further support the specificity of the shRNA-
mediated effects.
Next, the necessity of HOXA9 expression for survival of
primary AML patient samples was assessed. First, we confirmed
a high transduction efficiency (	 80%) in primary AML cells by
puromycin selection after transduction with control shRNA
constructs (data not shown) and determined that HOXA9shRNA
transduction efficiently suppressed HOXA9 expression com-
pared with control (Figure S10). We then analyzed the effect of
HOXA9 knockdown in MLL-rearranged and nonrearranged
primary human AML cells (6 MLL-rearranged 6 MLL germline).
Similar to our findings in cell lines and to previous publica-
tions,14-16 we find significantly higher HOXA9 mRNA expres-
sion in MLL-rearranged AMLs (P  .004; Figure 5A,B). Analy-
sis of apoptosis induction by annexin V staining demonstrated a
significant effect on MLL-rearranged leukemias with a mean
viability/control of 91% in the MLL-germline group versus 31%
in the MLL-rearranged group (P  .010; Figure 5C,D). More-
over, induction of apoptosis was significantly correlated with
HOXA9 expression level before lentiviral transduction
(R  0.8, P  .005; Figure 5E). These data were also con-
firmed in independent repeat experiments and demonstrate that
primary human MLL-rearranged AML samples remain depen-
dent on HOXA9 expression for their survival.
In vivo assessment of HOXA9 suppression
Next, we assessed the in vivo effect of HOXA9 suppression by
transplanting luciferase-positive t(4;11) SEMK2 cells into SCID-
beige mice followed by subsequent in vivo bioluminescent imag-
ing. In 2 independent experiments, 5 million SEMK2 cells/mouse
were transduced with either the 1F3-HOXA9shRNA construct or
GFP control shRNA and injected intravenously 24 hours after
transduction. Injection of equal numbers of transplanted cells was
confirmed by determination of total body luminescence 2 hours
after transplantation, and there was no significant difference
(Figure 6A). Longitudinal in vivo imaging revealed a significant
difference in total body luminescence as early as 24 hours after
transplantation (P  .036). This difference increased progressively
Figure 5. HOXA9 suppression induces apoptosis in
primary MLL-rearranged human AML cells. (A) Analy-
sis of baseline HOXA9 expression before shRNA trans-
duction by quantitative real-time PCR. (B) The mean
HOXA9 expression level was found to be significantly
higher in primary AML patient samples bearing an MLL
translocation (P  .004). (C) Analysis of apoptosis induc-
tion by annexin V staining 72 hours after transduction
with the 1F3-HOXA9shRNA or control shRNA. (D) Induc-
tion of apoptosis is significantly higher in the MLL-
rearranged group (P  .010). (E) A significant correlation
between baseline HOXA9 expression and impact of
HOXA9 knockdown on viability is demonstrated. Samples
expressing high-level HOXA9 were found to be espe-
cially susceptible to HOXA9 depletion (R  0.8;
P  .005).
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over time with a maximum at day 14 (P  .001) shortly before the
mice in the GFP shRNA control group began to die of leukemia
(Figure 6A,B). A subset of mice were killed at day 14 and assessed
for the number of human cells present in spleens from each group
of mice (Figure 6C). There was an approximately 40-fold differ-
ence in the number of human cells found in the spleens of the
2 groups of mice (P  .001; Figure 6D). Furthermore, there was a
significant difference in the spleen weights between mice that
received control-transduced cells and those that received
HOXA9shRNA-transduced cells (Figure 6E). Thus, continued
expression of HOXA9 is required for survival/proliferation of
SEMK2 cells in vivo.
Even though there was a dramatic difference in the number of
human cells present in the 2 groups of mice, some human cells
could be found in the mice that received HOXA9shRNA-
transduced SEMK2 cells (Figure 6C). We reasoned that the
presence of these cells could indicate either the presence of a
subpopulation of cells that do not require HOXA9 or the presence
of cells that have escaped HOXA9 suppression. Thus, we sorted
SEMK2 cells from both groups and assessed HOXA9 expression by
quantitative real-time PCR. We compared expression levels to
untreated SEMK2-M1 cells growing in culture and to SEMK2 cells
48 hours after transduction with the HOXA9shRNA construct. As
expected, assessment before transplantation showed a significant
decrease of HOXA9 expression in the transduced cells (Figure 6F).
Interestingly, the cells sorted at day 14 from mice transplanted with
HOXA9shRNA-transduced SEMK2 cells showed no significant
difference compared with cells isolated from mice transplanted
with GFP shRNA-transduced cells (P  .244; Figure 6F). This
demonstrates that the few human cells found in the mice that
received HOXA9shRNA-transduced SEMK2 cells have escaped
HOXA9 suppression. Therefore, cells expressing high-level HOXA9
have a growth and survival advantage in vivo, and there does not
appear to be a significant population of cells that are less dependent
on HOXA9 expression for their survival/proliferation. These results
were also confirmed applying a second HOXA9shRNA construct
(2A5-HOXA9shRNA) in an independent in vivo experiment
(Figure S11A-E). As in the in vivo experiment comparing 1F3-
HOXA9shRNA or GFP-control-shRNA transduced SEMK2 cells,
human cells present in the spleens of SCID-beige mice transplanted
with 2A5-HOXA9shRNA or GFP-control-shRNA-transduced
SEMK2 cells were isolated at day 14. Assessment of HOXA9
expression showed no significant difference in both groups
(P  .195; Figure S11D). Next, to determine whether the few
isolated cells from the 2A5-HOXA9shRNA-transduced group
were susceptible to subsequent HOXA9 suppression, cells were
transduced with the 1F3-HOXA9shRNA construct or the GFP-
control shRNA construct and viability in liquid culture was
assessed. Seven days after transduction, a highly significant
decreased number of viable cells was observed in cells transduced
with the 1F3-HOXA9shRNA construct compared with cells trans-
duced with the GFP-control shRNA (P  .001; Figure S11E). This
demonstrates that the cells remained susceptible to HOXA9 suppres-
sion and further supports the notion that the small population of
human cells found in the mice that received 2A5-HOXA9shRNA-
transduced SEMK2 cells was not rendered HOXA9 independent
but has rather escaped HOXA9 suppression in vivo.
Discussion
Comparative analysis of gene expression profiles in human
acute myeloid and lymphoblastic leukemias implicates up-
regulation of a subset of HOX genes as a central mechanism of
Figure 6. Assessment of the effects of HOXA9 suppres-
sion in vivo using bioluminescent imaging. (A) Before
transplantation, SEMK2 cells were transduced with either
1F3-HOXA9 shRNA or GFP control shRNA and injected
intravenously 24 hours after transduction. Mice were imaged
2, 24, and 72 hours after injection and then weekly. (B) There
was no significant difference in total body luminescence
2 hours after injection confirming that an equal number of
treated cells was injected (P .101). Repetitive longitudinal
in vivo bioluminescent imaging at later time points revealed a
significant difference of total body luminescence as early as
24 hours after transplantation (P .036). Fourteen days after
transplantation, the differences in total body luminescence
reached a significant maximum (P .001), shortly before the
GFP shRNA–treated control group died of overt leukemia.
(C) The degree of leukemic organ infiltration in both groups
was assessed.The percentage of hCD19/mCD45SEMK2
cells was evaluated in spleens from wild-type SCID-beige
mice that received 1F3-HOXA9–transduced or GFP-control–
transduced cells. (D) The total number of human cells/spleen
is graphed for both groups of mice. There is a 40-fold
difference in total number of SEMK2 between groups
(P .001). (E) Spleen weights for are shown for mice that
received either control or 1F3-HOXA9-transduced SEMK2
cells. (F) Analysis of HOXA9 expression in SEMK2 cells at
the day of transplantation (day 0) confirmed efficient HOXA9
suppression (80%) in the 1F3-HOXA9 shRNA-treated group
compared with control shRNA-transduced cells. Human cells
were isolated from mice that received either control or
1F3-HOXA9 shRNA-transduced SEMK2 cells 14 days after
injection, and the HOXA9 expression level was compared
with SEMK2 cells growing in culture. The HOXA9 expression
level at this time point was similar in the sorted SEMK2 cells
from the 1F3-HOXA9shRNA group as in those sorted from
the GFP shRNAcontrol group (P .244).
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leukemic transformation by MLL oncoproteins.14-16,21,22,61,62
Gene expression studies in murine models also demonstrate
high-level expression of Hox genes in Mll-fusion initiated
murine leukemias and leukemia stem cells.27,28 The central role
for HOX genes is further supported by recent studies that have
identified HOX genes as direct binding targets for wild-type
MLL and MLL-fusion proteins.30-32 However, experiments in
murine leukemia models directly assessing the requirement for
specific Hox genes in Mll-rearranged leukemias have produced mixed
results, perhaps because the Hox gene of interest is most often deleted in
the germline and thus not present during leukemia initiation. Such
models assess the necessity for a gene product to initiate leukemia, but
they may not assess the continued requirement of a particular gene in a
fully developed leukemia.
To further investigate the possibility that HOXA9 is neces-
sary for survival of human leukemias, we used a lentiviral-based
shRNA approach to inhibit HOXA9 in human leukemia cell
lines and primary AML patient samples. We demonstrate that
HOXA9 depletion leads to an almost immediate reduction of
proliferative capacity, differentiation, and subsequent progres-
sive induction of apoptosis, which was rescued by ectopic
overexpression of HOXA9. The effect on apoptosis induction
was significantly more pronounced in cells carrying an MLL-
fusion than in cells with MLL germline karyotype; however,
even MLL germline cells possessing high-level HOXA9 expres-
sion demonstrated enhanced sensitivity to HOXA9 suppression.
Furthermore, we demonstrate that HOXA9 suppression is also
required for appropriate proliferation/survival in vivo. Global
expression analysis after HOXA9 suppression revealed a tight
correlation between HOXA9 suppression and subsequent down-
regulation of a gene set previously identified to be overex-
pressed in murine MLL-leukemia stem cells and human MLL-
AML including 5-HOXA cluster genes, the HOXA9 cofactors
MEIS1 and PBX3, and the transcription factor MEF2C. Al-
though part of the observed expression changes might be the
result of an already initiated apoptosis program rather than a
direct effect of HOXA9 suppression, these findings further
support HOXA9 as a central downstream target of select
MLL-fusion proteins, which contributes to the induction and
maintenance of an inappropriate gene expression program also
found in primary human AML and in leukemogenic progenitor
populations.28,29 The fact that some but not all genes aberrantly
expressed in murine MLL leukemia stem cells and primary
human MLL leukemias are also part of the HOXA9 suppression
signature implies that MLL-fusion oncogene-mediated leuke-
mic transformation is also mediated by other dysregulated
pathways independent from HOXA9.
Our data showing that transplantation of HOXA9 depleted,
human t(4;11) SEMK2 cells into SCID-beige mice revealed a
significant decrease in leukemia burden in vivo supports the
concept that HOXA9 is crucial for survival of MLL-rearranged
leukemias. It has been proposed previously that there may be
functional redundancy within members of the clustered HOX
genes such that suppression of any one HOXA cluster gene may
be compensated for by the high-level expression of other HOXA
genes. In contrast, the data presented here reveal a significant
effect of HOXA9 suppression, which could not be compensated
by other mechanisms to maintain cell proliferation/survival. We
note in our gene expression analysis that expression of other
5-HOXA cluster genes shows a significant decrease after
HOXA9 suppression. Extensive differences in sequence between
HOXA9 and other Homeobox genes in the shRNA-targeted
regions and similar expression changes with 2 different HOXA9-
shRNAs suggest that the shRNAs are not directly suppressing
other HOX genes. Therefore, the observed decrease of gene
expression of other HOX genes appears to be a result of
decreased HOXA9 expression, and sustained HOXA9 gene
expression is necessary for growth/survival of human MLL-
rearranged leukemias.
Demonstration that continued HOXA9 expression is required
for leukemia survival has potential therapeutic implications.
Although it is well known that HOX gene expression is a
frequent characteristic of both human acute leukemias and some
solid tumors, most notably ovarian carcinoma, it has remained
unclear whether such expression is required to maintain tumor
survival. Therefore, the therapeutic potential of HOX-associated
gene expression programs remained unclear. The demonstration
that suppression of HOX gene expression leads to growth arrest
in human MLL-rearranged leukemia cell lines and primary
patient samples and subsequent down-regulation of other leuke-
mia associated genes prompts further study of methods to inhibit
HOX gene function and their downstream-associated programs.
Having identified a gene signature after HOXA9 suppression
that is associated with the abrogation of survival of MLL-
rearranged human leukemias, it might be possible to use this
“HOXA9-associated leukemia abrogation signature” for gene
expression-based screening approaches of small molecule librar-
ies as previously successfully demonstrated.63-65 Another ap-
proach would combine in vivo RNA interference conjugated to
monoclonal antibodies to specifically target leukemia cells and
suppress HOXA9-dependent pathways necessary for leukemia
survival. It has been demonstrated in a recent proof-of-principle
experiment that this approach might be feasible.66 Such novel
therapeutic approaches might prove particularly useful in high
risk MLL-rearranged leukemias. A similar approach can now be
used to assess the importance of HOX gene expression in other
tumor types.
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